From data to decisions: Efficient biomarker integration to enable insights in global clinical programs

Precision Oncology webinar with experts Alan Arnold and Erin Newburn

Graphical Summary: Validation of an automated, scalable comprehensive genomic profiling assay for hematologic malignancies

Key TakeawaysLabcorp Pan-Heme NGS demonstrates high sensitivity and specificity.This test may be used to help guide clinical decisions in both myeloid and lymphoid malignancies. 

Biomarkers and Precision Medicine 2025

Advancing precision medicine for greater patient access to your breakthrough therapyLabcorp provides integrated solutions across the entire precision medicine pathway—from biomarker identification and clinical trial assay development to CDx validation and commercialization. 

The promises and perils of biomarker testing in gynecologic cancers

Check out our latest clinical commentary in Gynecologic Oncology, where we examine how biomarker testing is transforming the care of patients with gynecologic cancers. Precision medicine is unlocking new possibilities through innovations like next-generation sequencing (NGS), liquid biopsy, tumor-agnostic therapies, and molecular stratification—but the pace of progress also brings practical challenges.To fully realize the potential of biomarker-driven care, we need clear clinical pathways, equitable access, and stronger education for providers and patients alike. Without them, we risk missing key opportunities to deliver the most effective, personalized treatment possible.

Maximizing genomic biomarker detection with liquid biopsy profiling

When tumor tissue is limited or unavailable, precision oncology can still deliver answers. Once viewed only as a backup to tissue testing, liquid biopsy use cases continue to expand in both clinical trials and patient diagnostics. By analyzing circulating tumor DNA (ctDNA) from a simple blood draw, liquid biopsy-based comprehensive genomic profiling (CGP) offers a scalable, non-invasive solution that expands access to biomarker testing, even in patients with limited biopsy options.Ellen Verner, senior manager, CLIA analysis at Labcorp’s CAP/CLIA oncology laboratory in Baltimore, MD, U.S., shared how the liquid biopsy-based Labcorp® Plasma Complete test addresses real-world challenges and supports clinical and biopharma research efforts alike.